2023 World Conference on Lung Cancer (Posters)-P1.25. Real-World Outcomes in Non-metastatic Non-small Cell Lung Cancer (NSCLC): An I-O Optimise Multi-Country Analysis

P1.25. Real-World Outcomes in Non-metastatic Non-small Cell Lung Cancer (NSCLC): An I-O Optimise Multi-Country Analysis - PDF(Abstract)

Back to course

Pdf Summary

This study conducted a multi-country analysis to investigate real-world outcomes in patients with non-metastatic non-small cell lung cancer (NSCLC). The researchers analyzed data from various sources, including a Canadian database, a German registry, and national registries in Sweden and the UK. They examined patient characteristics, initial treatment, and overall survival (OS) for patients diagnosed between 2008 and 2020.<br /><br />The results showed that the proportions of patients diagnosed at each disease stage varied across data sources. The rates of resection (surgery with other treatments) and non-resection (only non-surgical treatments) were similar for stage I and II NSCLC, but the resection rates were lower for stage III NSCLC. The proportion of untreated patients ranged from 5% to 30%, with higher rates of untreated patients in the stage III subcategories.<br /><br />Overall, resected patients with stage I-II NSCLC had the longest median OS, while unresected patients diagnosed at stage III had the shortest median OS. Survival probabilities consistently decreased with increasing stage, indicating a need for improved therapeutic approaches, particularly for patients with stage II or III NSCLC.<br /><br />The study found comparable findings across data sources, but also identified some differences, especially in the distribution of stage at diagnosis and the proportions of resected and unresected patients among those with stage III disease.<br /><br />In conclusion, this large-scale analysis provides valuable insights into real-world outcomes for patients with non-metastatic NSCLC. The findings highlight the importance of personalized treatment approaches to improve survival rates, especially for patients with advanced stage disease. Further research is needed to develop innovative therapies for these patients.

Asset Subtitle

Melinda Daumont

Meta Tag

Speaker Melinda Daumont

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

non-metastatic non-small cell lung cancer

real-world outcomes

patient characteristics

overall survival

resection rates

untreated patients

median OS

therapeutic approaches

advanced stage disease

improve survival rates